A 58-year-old breast cancer survivor who gained significant weight during tamoxifen therapy lost 18.5 kg over 12 months using liraglutide, a GLP-1 medication, while her insulin resistance and blood sugar control normalized. According to Gram Research analysis of this 2026 case report, liraglutide reversed metabolic dysfunction that diet and exercise alone could not improve, though this single case suggests larger studies are needed to confirm effectiveness for other patients.
A 58-year-old breast cancer survivor who gained significant weight during cancer treatment found relief with a diabetes medication called liraglutide. After two years of tamoxifen therapy (a common breast cancer drug), she developed weight gain, prediabetes, and metabolic problems despite diet and exercise efforts. When doctors added liraglutide, she lost 41 pounds over one year and her metabolic health improved dramatically. According to Gram Research analysis, this case report suggests that GLP-1 medications might help cancer patients reverse treatment-related weight gain and metabolic dysfunction, though larger studies are needed to confirm these findings.
Key Statistics
A 2026 case report documented that a breast cancer survivor lost 18.5 kg (41 pounds) over 12 months of liraglutide treatment while continuing tamoxifen therapy, with insulin resistance scores normalizing from 4.9 to healthy levels.
In this single case, liraglutide reversed prediabetes and metabolic dysfunction in a tamoxifen-treated breast cancer survivor, achieving weight loss and metabolic improvements that had not been possible with diet and exercise alone over the previous 24 months.
A 58-year-old postmenopausal breast cancer patient treated with liraglutide experienced normalization of HbA1c and cholesterol levels alongside 41-pound weight loss, suggesting GLP-1 medications may address treatment-related metabolic complications in cancer survivors.
The Quick Take
- What they studied: Whether a GLP-1 medication called liraglutide could help a breast cancer survivor lose weight and improve metabolic health problems caused by tamoxifen cancer treatment.
- Who participated: One 58-year-old postmenopausal woman with hormone-receptor positive breast cancer who had been taking tamoxifen for 24 months and experienced significant weight gain despite trying diet and exercise.
- Key finding: The patient lost 18.5 kg (41 pounds) over 12 months of liraglutide treatment, and her insulin resistance and blood sugar control normalized, while continuing tamoxifen therapy without problems.
- What it means for you: If you’re a breast cancer survivor struggling with weight gain from treatment that hasn’t improved with lifestyle changes, liraglutide might be worth discussing with your doctor. However, this is one patient’s experience—more research is needed before doctors can widely recommend this approach.
The Research Details
This is a case report, which means doctors documented the medical history and treatment of one specific patient. The 58-year-old woman had been taking tamoxifen (a hormone therapy for breast cancer) for 24 months when she developed significant weight gain, prediabetes, high cholesterol, and insulin resistance—all despite following diet and exercise recommendations.
Doctors then prescribed liraglutide, a medication originally developed for type 2 diabetes that works by mimicking a natural hormone in the body that helps control appetite and blood sugar. They gradually increased her dose to 3.0 mg per day over several weeks. Researchers tracked her weight, blood sugar control (measured by HbA1c), insulin resistance (measured by HOMA-IR), and cholesterol levels over the next 12 months.
Throughout the treatment, she continued taking tamoxifen for her cancer without any problems. This is important because doctors needed to confirm that adding liraglutide didn’t interfere with her cancer treatment.
This research matters because tamoxifen-related weight gain is a real problem for many breast cancer survivors, and lifestyle changes alone often don’t work. Understanding whether medications like liraglutide could help is important for improving quality of life after cancer treatment. This case report serves as a starting point for larger, more rigorous studies.
This is a single case report, which is the lowest level of scientific evidence. It shows what happened to one patient, but we can’t know if the same results would happen to others. The patient’s improvement was substantial and well-documented with actual lab measurements, which strengthens the case report. However, we don’t know if other factors (like changes in diet or activity) contributed to the results. Larger randomized controlled trials would be needed to prove that liraglutide causes this benefit.
What the Results Show
Over 12 months of liraglutide treatment, the patient lost 18.5 kg (approximately 41 pounds), which represents a substantial reversal of the weight she had gained during tamoxifen therapy. This weight loss exceeded what doctors typically see with diet and exercise alone in similar patients.
Her metabolic health improved significantly. Her HOMA-IR score (a measure of insulin resistance) dropped from 4.9 to normal levels, meaning her body was no longer struggling to process blood sugar. Her HbA1c (a measure of average blood sugar over three months) also normalized, indicating her prediabetes had reversed. Her cholesterol levels improved as well.
Importantly, she continued taking tamoxifen throughout the liraglutide treatment without any adverse effects or complications. This suggests that combining these two medications is safe and doesn’t interfere with cancer treatment.
The case report notes that the patient’s improvement was particularly notable because it occurred despite the ongoing use of tamoxifen, which typically causes weight gain and metabolic problems. The fact that liraglutide worked while she continued cancer treatment suggests the medication addresses the underlying metabolic dysfunction caused by tamoxifen, rather than just causing general weight loss.
Very few cases of liraglutide successfully reversing tamoxifen-related weight gain have been reported in medical literature. This case adds to a small but growing body of evidence suggesting that GLP-1 receptor agonists might be useful for managing metabolic side effects of cancer treatment. The results align with what we know about how liraglutide works in other populations with insulin resistance and weight gain.
This is a single patient case, so we cannot know if these results would occur in other people. Different patients might respond differently based on genetics, other medications, diet, and lifestyle. We don’t have a comparison group (people who didn’t take liraglutide) to prove that the medication caused the improvement rather than other factors. The patient may have made unmeasured changes to diet or exercise. Larger, controlled studies are needed to determine if this approach works for most breast cancer survivors with tamoxifen-related weight gain.
The Bottom Line
If you’re a breast cancer survivor experiencing significant weight gain and metabolic problems from tamoxifen that haven’t improved with diet and exercise, discuss liraglutide with your oncologist and primary care doctor. This case suggests it may help, but evidence is still limited. Your doctors can assess whether it’s appropriate for your specific situation. Confidence level: Low to Moderate (based on one case report; stronger evidence would come from larger studies).
Breast cancer survivors taking tamoxifen who have experienced weight gain, prediabetes, or metabolic dysfunction despite lifestyle efforts should pay attention to this research. Oncologists and primary care doctors treating these patients should also be aware. People without cancer history should not assume liraglutide will work the same way for them, as the context of cancer treatment is unique.
In this case, meaningful weight loss began within the first few months and continued over 12 months. Metabolic improvements (blood sugar and insulin resistance) also took several months to normalize. If you were to try this approach, you should expect to give it at least 3-6 months to see results, with ongoing monitoring by your doctors.
Frequently Asked Questions
Can liraglutide help with weight gain from breast cancer treatment?
This case report suggests liraglutide may help reverse tamoxifen-related weight gain and metabolic problems, with one patient losing 41 pounds and normalizing blood sugar control over 12 months. However, this is one patient’s experience—larger studies are needed to confirm effectiveness for others.
Is it safe to take liraglutide while on tamoxifen for cancer?
In this case report, the patient continued tamoxifen throughout liraglutide treatment without adverse effects or complications. However, you must discuss any new medication with your oncologist to ensure it won’t interfere with your cancer treatment plan.
How much weight can I expect to lose with liraglutide if I’m a cancer survivor?
This single patient lost 18.5 kg (41 pounds) over 12 months, but results vary by individual. Factors like genetics, diet, exercise, and other medications affect outcomes. Your doctor can help set realistic expectations based on your specific situation.
What if diet and exercise haven’t helped my tamoxifen weight gain?
This case suggests liraglutide may help when lifestyle changes alone haven’t worked, achieving improvements in weight and metabolic health. Discuss this option with your oncologist and primary care doctor to determine if it’s appropriate for you.
How long does it take to see results from liraglutide?
In this case, meaningful weight loss and metabolic improvements developed over 12 months of treatment. Most people should expect to give any new medication at least 3-6 months to assess effectiveness before deciding whether to continue.
Want to Apply This Research?
- Track weekly weight, monthly fasting blood glucose levels, and quarterly HbA1c results (if available through your doctor). Also log any side effects from liraglutide and how you’re feeling overall.
- Use the app to set a goal of continuing your current diet and exercise routine while starting liraglutide (if prescribed by your doctor). Track adherence to the medication schedule and any appetite changes you notice.
- Create a long-term dashboard showing weight trend over months, metabolic markers (blood sugar, insulin resistance) from lab results, and energy levels. Set monthly check-in reminders to review progress with your healthcare provider and adjust the plan as needed.
This case report describes one patient’s experience and should not be interpreted as medical advice or proof that liraglutide will work for all breast cancer survivors. Weight gain during tamoxifen therapy is complex and individual responses to treatment vary significantly. Before starting liraglutide or any new medication, consult with your oncologist and primary care physician to discuss whether it’s appropriate for your specific medical situation, potential side effects, and interactions with your current cancer treatment. This research is preliminary; larger clinical trials are needed to establish the safety and effectiveness of GLP-1 receptor agonists for managing tamoxifen-related metabolic complications. Do not discontinue or modify any cancer treatment without explicit guidance from your healthcare team.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.